US7091321B2 - Enhancing the circulating half-life of antibody-based fusion proteins - Google
Patents US7091321B2 - Enhancing the circulating half-life of antibody-based fusion proteins …

Disclosed are methods and compositions for efficiently expressing antibody fusion proteins.
Antibody fusion pro teins of the invention include a hybrid antibody moiety containing …

4,196,265 A 4/1980 Koprowski et al. 4,469,797 A 9/1984 Albarella 4,522,811 A 6/1985
Eppstein et al. 4,667,016 A 5/1987 Lai et al. 4,676.980 A 6/1987 Segal et al. 4,703,008 A …

The invention relates to protein complexes and fusion proteins including at least two
different cytokine molecules. The protein complexes and fusion proteins may further include …

US20060210561A1 - Dosages for treatment with anti-EGFR antibodies - Google Patents
US20060210561A1 - Dosages for treatment with anti-EGFR antibodies - Google Patents …

Methods of treatment of various bone indications, such as osteoporosis, in a mammal are
provided Wherein an effective amount of an antagonist that binds to a B-cell surface marker …

Tumors are identified as responsive to treatment with HER dimerization inhibitors (HDIs) are
identified by treating a HER expressing tumor with an HDI (which may be the same or …

Disclosed are methods and compositions for efficiently expressing antibody fusion proteins.
Antibody fusion pro teins of the invention include a hybrid antibody moiety containing …

5,514,582 A 5/1996 Capon et al. fusing the preselected antigen to an immunoglobulin heavy
5,538,866 A* 7/1996 Israeli et al. chain constant region to produce an Fc-antigen fusion pro …

The present invention describes polynucleotides and polypeptides that have been
discovered to correlate to the relative intrinsic Sensitivity or resistance of cells, eg, colon cell …